- All sections
- C - Chemistrymetallurgy
- C07F - Acyclic, carbocyclic, or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
- C07F 9/6561 - Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Patent holdings for IPC class C07F 9/6561
Total number of patents in this class: 1603
10-year publication summary
|
113
|
132
|
127
|
95
|
118
|
110
|
122
|
131
|
135
|
83
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Gilead Sciences, Inc. | 2220 |
121 |
| The Regents of the University of California | 20720 |
34 |
| Achillion Pharmaceuticals, Inc. | 157 |
25 |
| Samsung Display Co., Ltd. | 38570 |
24 |
| Merck Sharp & Dohme LLC | 3735 |
21 |
| LG Chem, Ltd. | 17921 |
19 |
| Sarepta Therapeutics, Inc. | 387 |
19 |
| Rigel Pharmaceuticals, Inc. | 507 |
17 |
| Cipla Limited | 476 |
13 |
| Novartis AG | 10263 |
12 |
| Bristol-myers Squibb Company | 4729 |
12 |
| LT Materials Co., Ltd. | 444 |
12 |
| Shanghai Institute of Materia Medica, Chinese Academy of Sciences | 870 |
11 |
| Shionogi & Co., Ltd. | 873 |
11 |
| Forward Therapeutics, Inc. | 21 |
11 |
| Glaxosmithkline Biologicals S.A. | 1601 |
10 |
| Eisai R&D Management Co., Ltd. | 1166 |
10 |
| Centre National de La Recherche Scientifique | 11016 |
9 |
| The Johns Hopkins University | 5875 |
9 |
| Cancer Targeted Technology LLC | 28 |
9 |
| Other owners | 1194 |